Sandhya Mehta

Articles by Sandhya Mehta

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

ByAnushree Iyengar,Sandhya Mehta,Hannah Barman,Nivedita Rangarajan,Sue-Ann Woo,Simone T. Sredni,Rosemarie Di Donato,Safak Simsek,Erinn P. Downs,Aziza Nassar,Darren M. Wilson,Katherine Krieser,Elise Bieri Patzke,Natalie Kyek,Jason Hipp,Tyler Wagner, PhD

May 25th 2025

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

ByChia Jie Tan,Connor Willis,Trang Au,Matthew Schabath, PhD,Chenghui Li,Kristen Kelley,Xiaoqing Xu,Leah Park,Clara Lam,Sandhya Mehta,Jackie Kwong,Diana Brixner,David Stenehjem

April 17th 2025

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

BySandhya Mehta,Kristin M. Zimmerman Savill,Peng Wang,Prathamesh Pathak,Clara Lam,Jackie Kwong,Bruce Feinberg

July 28th 2024

65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

BySandhya Mehta,Anupama Vasudevan,John Li,Dawn Brenneman,Jackie Kwong

May 7th 2024

Latest Updated Articles

Trending on CancerNetwork

Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer

Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer

Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma

Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma

Which New Service Lines Should a Radiation Oncology Department Launch?